Phase 1 clinical study that will evaluate the safety, tolerability, and preliminary efficacy of INCAGN02390, an antagonist antibody specific for TIM-3. INCAGN02390 is an aglycosylated fully human IgG1κ monoclonal antibody that selectively binds to human TIM-3 and is being developed for the treatment of advanced malignancies